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Antiplatelets-30%. ConClusions: CHA2DS2-VASc showed better prediction than 
CHADS2 for stroke risk prediction. Dabigatran was observed to have better out-
come followed by VKA and Anti-platelets.
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objeCtives: To evaluate the management of Chronic Thromboembolic Pulmonary 
Hypertension (CTEPH) in a referral hospital by assessing clinical variables, patient-
reported outcomes and caregivers’ burden. Methods: An observational, retrospec-
tive study was conducted. All patients (aged > 18 years) attending the specialised 
unit on CTEPH at the 12 de Octubre Hospital (Spain), between January 2010 and 
November 2012, were offered to participate. Clinical variables were recorded at 
the clinical session for treatment decision (Pulmonary endarterectomy –PEA- if 
operability was confirmed or medication therapy –MT- if inoperable), and after 
one year. Outcomes considered: The New York Heart Association Functional Class 
(FC), 6-Minute Walking Distance, pulmonary arterial pressure, pulmonary vascular 
resistance and pro-brain natriuretic peptide. Participants completed the EQ-5D and 
caregivers’ fulfilled the Zarit Burden Interview. Differences between groups were 
studied (Chi-squared, Mann-Whitney U and ANCOVA). Results: A total of 64 CTEPH 
cases (57.8% males) were included. Mean (SD) age at diagnosis was 55.8 (14.9) and 
67.2% had an III-IV FC at diagnosis. At the moment of treatment prescription, dif-
ferences in clinical variables were not found (all p> 0.4) between PEA (n= 35-54.7%-) 
and MT groups (n= 29-45.3%-). After 12 months, 8 patients died (2 in PEA group and 
6 in MT). Among survivors, FC was significantly better in PEA group (93.9% improved 
at least one level). Regarding EQ-5D, patients undergoing PEA showed significant 
higher utilities (0.83-0.17- vs. 0.53-0.31-p= 0.007) and VAS values (80.22-14.24- vs. 
49.47-20.68-p< 0.001). Furthermore, mean VAS values in PEA group were comparable 
to general population (adjusted by sex and age). Finally, formal care was needed 
by just 4.8% of patients in PEA versus 33.3% in MT. Reported caregivers’ burden 
were relatively low in both groups (p= 0.87). ConClusions: The positive outcomes 
obtained, especially in those patients undergoing PEA, suggest the experienced 
management of CTEPH by this referral hospital and highlights the importance of 
detecting candidates for PEA.
PCV22
the 3.5-year MOrtality iMPaCt Of drugs in seCOndary PreVentiOn 
Of MyOCardial infarCtiOn in real-life (interiM analysis Of the eOle 
COhOrt)
Droz C.1, Dureau C.2, Thomas D.3, Danchin N.4, Tricoire J.5, Benichou J.6, Paillard F.7, Hercberg 
S.8, Sibon I.9, Rouanet F.9, Rambelomanana S.2, Maizi H.2, Bernard M.A.2, Blin P.2, Moore N10
1INSERM CIC Bordeaux CIC 1401, Univ. Bordeaux, INSERM U657, Bordeaux, France, 2INSERM 
CIC Bordeaux CIC1401, Univ. Bordeaux, Bordeaux, France, 3Hôpital Pitié Salpétrière, Paris, France, 
4Hôpital Européen Georges Pompidou, Paris, France, 5Clinique Ambroise Paré, Toulouse, France, 
6CHU de Rouen, INSERM U657, Rouen, France, 7CHU de Pontchaillou, Rennes, France, 8INSERM 
U557, Bobigny, France, 9CHU de Bordeaux, Bordeaux, France, 10INSERM CIC Bordeaux CIC1401, 
Univ. Bordeaux, INSERM U657, CHU Bordeaux, Bordeaux, France
objeCtives: Few studies have assessed the real-life impact of secondary prevention 
drugs on all-cause mortality post-myocardial infarction (MI), especially in countries 
with low incidence of MI. The objective of this interim analysis after 3.5-year of follow-
up was to assess the real-life all-cause mortality impact of drugs reimbursed for 
MI secondary prevention in France: acetylsalicylic acid (ASA), anti-platelet agents 
(APA), beta-blockers (ß-), angiotensin converting enzyme inhibitors (ACEI), statins, and 
omega-3 supplementation (Om3). Methods: Cohort study of patients with recent 
(≤ 3 months) acute MI included by hospital and non-hospital cardiologists, with 6-year 
follow-up. Vital status was obtained from the National death registry, and failing that 
by patient/relatives/physicians investigation. Drug exposure was defined using both 
physician and patient reports at inclusion. Cox proportional hazard model was used 
to estimate for each drug, mortality hazard ratio (HR) of exposed versus non exposed 
patients, adjusted for gender, age, cardiovascular risk factors, other MI prevention 
drugs, and propensity score to be exposed at inclusion. Results: Between May 2006 
and June 2009, 596 physicians included 5538 patients: mean age 62.1 years, 77.6% male, 
9.6% current smokers, 14.5% diabetic, 44.6% hypercholesterolemic, 43.6% hyperten-
sive, 8.2% with LVEF < 40%. At inclusion, 97.5% were exposed to ASA, 91.0% to APA, 
89.7% to ß-, 71.1% to ACEI, 92.0% to statins, and 15.7% to Om3. The 3.5-year mortality 
was 7.8% (95%CI [7.1%-8.5%]) with an incidence rate of 23.2 per 1000 patient-years. 
Adjusted HR were: 0.98 [0.60-1.61] for ASA, 0.86 [0.60-1.24] for APA, 0.84 [0.63-1.11] 
for ß-, 0.80 [0.61-1.03] for ACEI, 0.67 [0.45-1.00] for statins, and 0.82 [0.58-1.16] for 
Om3. ConClusions: The 3.5 year interim all-cause real-life death reduction point 
estimates were close to those of large randomized controlled trials, except for ASA, 
for which almost all patients were exposed. The study’s statistical power will be suf-
ficient to confirm or not these trends at the final 6-year analysis.
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objeCtives: In 2012, the NHS Health and Social Care Information Centre (HSCIC), 
with support from NICE, reported on the eligible population for ezetimibe as a 
second-line lipid-lowering therapy (LLT) in England. Several populations were 
omitted from this analysis, including some very high-risk Type 2 Diabetes Mellitus 
(T2DM) patients with CVD. We re-evaluated the eligible population for ezetimibe 
indicated for treatment intensification in a retrospective analysis. Methods: 
Patients with ≥ 1 total cholesterol (TC) measure in each year of interest were iden-
objeCtives: To critically appraise the published network meta-analyses (NMAs) 
evaluating the efficacy or safety of the new oral anticogulants (NOACs) dabigatran, 
rivaroxaban and apixaban for the prevention of stroke in patients with non-valvular 
atrial fibrillation (AF). Methods: A systematic literature review was performed to 
identify the relevant NMAs using MEDLINE®, EMBASE®, Cochrane Library, Database 
of Abstracts of Reviews of Effects, and Health Technology Assessment. The synthesis 
studies were evaluated using the ‘Questionnaire to assess the relevance and cred-
ibility of the NMA’. Results: Eleven NMAs evaluating NOACs among adults with 
non-valvular AF were identified. Most NMAs included three large phase III RCTs, 
comparing NOACs to adjusted-dose warfarin (RE-LY, ROCKET-AF, ARISTOTLE). The 
main differences identified related to potential treatment effect modifiers regard-
ing the mean time spent in therapeutic range (TTR) in the warfarin arm, the risk of 
stroke or systemic embolism across the trials (mean CHADS2 score: Cardiac failure, 
Hypertension, Age ≥ 75 years, Diabetes mellitus, Stroke, 2 two points for stroke) or 
primary versus secondary prevention, and type of populations used in the analysis. 
Kansal et al. appropriately adjusted the ROCKET-AF TTR to match the RE-LY popula-
tion based on individual patient data. Meta-regressions are not expected to mini-
mize confounding bias given limited data, whereas subgroup analyses had some 
impact on the point estimates for the treatment comparisons. ConClusions: 
Results of the synthesis studies were generally comparable and suggested the 
NOACs had similar efficacy, although some differences were identified depending 
on the outcome. The extent to which the differences in the distribution of TTR, 
CHADS2 or primary versus secondary prevention biased the results remains unclear.
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objeCtives: To examine recommended target levels of low-density lipoprotein 
cholesterol (LDL-C) for hyperlipidaemia patients at high risk (i.e., with two or more 
risk factors or coronary heart disease or its risk equivalents) for cardiovascular dis-
ease (CVD); to determine the proportions of patients who do not achieve targeted 
LDL-C levels in real-world setting studies. Methods: A targeted literature review 
identified guidelines and real-world studies that analysed hyperlipidaemia patients 
who were not at goal (as defined by study). MEDLINE, Embase, the Cochrane Library, 
and BIOSIS databases were searched. Guideline publications were searched from 
2008; observational studies were searched from January 2005 to December 2013. 
There were no language or geographical restrictions. Results: 17 guidelines and 
70 observational studies were included in the review. While country-specific guide-
line recommendations vary slightly, the commonly used European Atherosclerosis 
Society and European Society of Cardiology (EAS/ESC) guidelines recommend a 
LDL-C target of < 2.5 mmol/L for patients with high CVD risk. Most studies reported 
that between 61.8% and 95.4% of high-risk patients did not reach this target. 3 
studies from North America reported lower proportions, between 18.9% and 42.3%. 
The EAS/ESC guidelines recommend a LDL-C target of < 1.8 mmol/L for patients 
with very high CVD risk. Studies reported that 68.1% to 96.0% of patients do not 
achieve this goal. ConClusions: Patients in higher cardiovascular-risk categories 
tend to have more stringent LDL-C target levels, which may contribute to failure to 
achieve target levels. This suggests several unmet needs: large numbers of patients 
who fail to achieve LDL-C targets, reducing the patients’ risk for CVD, and conse-
quently reduce the occurrence of cardiovascular events. Based on recently published 
American College of Cardiology and American Heart Association guidelines, which 
do not recommend a treatment target LDL-C level, further research is needed to 
re-evaluate the unmet need in hyperlipidaemia patients.
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objeCtives: Stroke Risk Stratification in AF patients of can be done using 
CHADS2 (Congestive heart failure, Hypertension, Age ≥ 75, DM, prior Stroke/TIA 
[2 points]); or CHA2DS2VASc2 (Congestive heart failure/left ventricular ejection 
fraction ≤ 35%, Hypertension, Age ≥ 75 [2 points], DM, prior Stroke/TIA/thrombo-
embolism [2 points], Vascular disease, Age 65–74, Sex- female). Treatment options 
for Prevention of stroke includes Anti-coagulants (Vitamin K Antagonist-Warfarin, 
Acenocoumarol; and Newer Oral Anticoagulant- Dabigatran) and anti-platelets 
(Aspirin and Clopidogrel). The objective of this study was to assess better tool 
for Stroke Risk Stratification; CHADS2 vs CHA2DS2VASc2 and to observe utiliza-
tion pattern of antithrombotics with stroke as the outcome. Methods: Elderly 
patients (Age> 65yrs) with Non-Valvular Atrial Fibrillation admitted in the hos-
pital within span of 2yrs (2012-13) were selected excluding patients with comor-
bidities like Atrial flutter, DVT, PFO, Endocarditis and/or ARF (after approval of 
ethical committee). Total of 160 patients were segregated based on stroke risk 
and percentage of patients experiencing thromboembolic event in each group 
was observed and CHADS2 and CHA2DS2-VASc were compared. The efficacy of 
antithrombotics in prevention of thromboembolic event in patients with AF was 
studied. Results: For stroke risk stratification, CHA2DS2-VASc was observed to 
be a better tool than CHADS2 to predict ‘truly low risk’, ‘moderate risk’ and ‘high 
risk’ patients. A shift of AF patients from ‘low-moderate risk’ by CHADS2 to ‘high 
risk’ by CHA2DS2VASc was noticed, 95% of patients required anticoagulation (either 
VKA or NOACs) as per CHA2DS2VASc, whereas, only 60% required OACs as per 
CHADS2. Most patients who experienced CVA belonged to ‘No antithrombotics 
prescribed’ group (25%). Dabigatran showed no incidence of CVA outcome, followed 
by VKA-, (Warfarin-28% and Acenocoumarol-18%) and least efficacy was seen by 
